anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This prospective randomized controlled study was approved by the IRB of our institute.

Patients requiring nasotracheal intubation will be screened for eligibility for the study. Then, patients will be randomized to one of two groups; (Group I: tube will be inserted through the left nostril and advanced into the oral cavity / Group II: tube will be inserted through the right nostril and advanced into the oral cavity). After induction of anesthesia and muscle relaxation, the preformed nasal RAE (Ring-Adair-Elwyn) tube will be inserted via the nostril, which is assigned to each patient according to the group, approximately 3-4 cm. Next, an anesthesiologist will advance the tube into the oral cavity. After the tube is placed in the oral cavity, the anesthesiologist will perform nasotracheal intubation with Magill forceps. After that, an investigator will check the occurrence of epistaxis due to nasotracheal intubation and its severity with a fiberoptic bronchoscope. After obtaining all data, investigators will analyze the incidence of epistaxis and its severity between the two groups.
The use of a of an alpha1beta1 function blocking antibody which is capable of binding an epitope of integrin VLA-1 in a medicament for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. Figure 18. A. Increasing concentrations of the human alpha1-I domain were bound to plates previously coated with 1 µg/ml collagen I (squares) or collagen IV (circles). Values shown have been corrected for background binding to BSA. B. 2 µg/ml human alpha1-I domain was mixed with increasing concentration of an anti-human al integrin antibody SE8D9 (squares) or an antihuman alpha 2-integrin antibody A2IIE10 (circles), and then bound to plates previously coated with 1 µg/ml collagen IV. C. Plates were coated with 1 µg/ml collagen IV or 3% BSA. 1-I domain (2 µg/ml) was subsequently bound to coated plates in the presence of 1mM Mn2+, 1mM Mg2+, or 5 mM EDTA. Data shown is representative of three independent experiments.
There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteriodal anti-inflammatory drugs [NSAIDs]). See WARNINGS. 

It is important to use the dose and dosing regimen as recommended (pm/am split dose). SeeDOSAGE and ADMINISTRATION.
FIELD: organic chemistry, heterocyclic compounds, biochemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of 6-arylpyrido[2,3-d]pyrimidine and naphthyridine, their pharmaceutically acceptable salts, a pharmaceutical composition showing an inhibitory effect on cellular proliferation induced by protein tyrosine kinase and a method of inhibition of cellular proliferation. Indicated properties of compounds will ensure to use their in the important biological processes in pathological mechanism and proliferative diseases, for example, cancer, atherosclerosis and restenosis. The proposed compounds correspond to the general formula (I)   where X means methine group or nitrogen atom; B means the group NR 3 R 4 ; each of R 1 ,R 2 ,R 3 ,R 4  means independently hydrogen atom, alkyl with 1-8 carbon atoms or residue Ar, or the group (A)  , and their pharmaceutically acceptable salts. Invention relates to also a pharmaceutical composition comprising at least one pharmaceutical carrier and a compound of the formula (I) as an active substance or its a pharmaceutically acceptable salt taken in effective amount and to a method of inhibition of cellular proliferation induced by protein tyrosine kinase by administration of a compound of the formula (I) in effective dose or its pharmaceutically acceptable salt in effective dose. EFFECT: new compounds indicated above, valuable medicinal properties. 46 cl, 2 tbl, 131 ex
The invention relates to an alopecia treatment formula. The formula comprises an external liniment and an internal traditional Chinese medicine preparation. The external liniment mainly comprises minoxidil. The internal traditional Chinese medicine preparation comprises traditional Chinese medicines having effects of invigorating blood circulation and tonifying kidney in the Chinese pharmacopeia. The external liniment containing minoxidil is used for expanding blood vessels in an alopecia part. Appropriate content of azone as a permeation assistant and glycerinum is used for promoting skin absorption of medicines and reducing a use amount of a western medicine minoxidil as a blood vessel expansion agent. The corresponding traditional Chinese medicine decoction pieces which can satisfy the Chinese pharmacopeia requirements and are subjected to liquid chromatogram-labeled fingerprint-based traditional Chinese medicine quality control are prepared into the unique hair-growth decoction preparation and the hair-growth decoction preparation has effects of invigorating blood circulation and tonifying kidney, adjusting the balance of factors in a human body and realizing alopecia treatment. The alopecia treatment formula realizes combination of the external western medicine liniment and the oral traditional Chinese medicine preparation, retains western medicine minoxidil effects of blood vessel expansion, does not adopt an oral medicine for inhibiting androgen synthesis, utilizes the oral traditional Chinese medicine mixture, keeps curative effects, reduces oral medicine side-effects and realizes alopecia treatment. The alopecia treatment formula can be used for beauty treatment such as female eyebrow restoration and male eyebrow thickening.
Participants randomly assigned to this condition will maintain their usual physical activity and exercise routine and not engage in any additional exercise than they were prior to the study. These participants will fill out questionnaires (\~20 minutes each time) following randomization into this condition, once per week for four weeks, and at 1-week, 1-month, and 3-months (\~20 minutes each time) follow-up. After completing the last follow-up, participants in the waitlist condition will be re-randomized into either the resistance training only or resistance training + Unified Protocol conditions.
Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
Children with developmental language disorders (DLD) have impaired morphosyntactic abilities despite age-appropriate nonverbal cognitive abilities and no hearing disorders or brain injury. The persistent omission of third-person object clitic pronouns (3DO clitics) has been proven to be a clinical marker of developmental language disorders (DLD) for both preschool and school-aged Italian-speaking children. According to the model of 3DO clitic derivation recently brought to attention, 3DO clitic omission is a morphosyntactic matter and, therefore, we argue that the production of 3DO clitics can be enhanced through morphosyntactic priming in children with DLD. To corroborate this hypothesis, we administered a 3DO clitic training based on a morphosyntactic priming paradigm to 23 typically developing (TD) children and 11 children with DLD. Results show that their 3DO clitic production is enhanced after the training and that these effects are persistent in time. Our results suggest that a priming-based training can concretely help children with DLD in their language development.
WARRIOR trial is a multi-site, PROBE design, that will evaluate an intensive statin/ACE-I (or ARB)/aspirin treatment strategy (IMT) vs. primary prevention risk factor therapy treatment strategy (UC) in 4,422 symptomatic (chronic angina or equivalent) women with non-obstructive CAD (\<50% diameter narrowing).

There will be \~80 US sites, including VA/ military and OneFlorida CDRN sites, with a proven record in prior trials. The investigators will use web-based, real-time data entry, and management University of Florida Data Management System (UFDMS) for site selection, screening, participant eligibility confirmation, enrollment, and randomization. Participants will be recruited from screened women with symptoms suspected to be ischemic with non-obstructive CAD by invasive coronary angiogram or CT angiogram. The high dose statin (atorvastatin or rosuvastatin) and ACE-I (lisinopril) \[or ARB (losartan)\] are generic commonly used medications previously demonstrated effective for improving angina, stress testing, myocardial perfusion and coronary microvascular flow reserve in small size trials in this population. Additionally, aspirin will also be recommended to IMT participants without contraindications or excess bleeding risk, however aspirin will not be provided by the study. Both the groups will also receive Lifestyle Counseling (PACE Assessment), and the same visit schedule and "face-time" with site staff to reduce bias. Events will be adjudicated by the Clinical Events Committee (CEC), according to objective criteria and masked to treatment assignment clues.
To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
AIMS: Coronary vasospasm is associated with acute coronary syndrome (ACS) and may persist during primary percutaneous coronary intervention (PCI). We aimed to elucidate the incidence, morphological characteristics, and prognostic impact of residual vasospasm in plaque rupture (PR) and plaque erosion (PE) lesions using optical coherence tomography (OCT).
METHODS: We enrolled 142 patients with ACS who underwent OCT-guided primary PCI. All patients received intracoronary vasodilators before OCT examination. Residual vasospasm was identified as intimal gathering and categorised as polygonal- or wavy- patterned depending on the luminal shape. A wavy pattern was defined as a curved intimal surface line. A polygonal pattern was defined as a lumen with multiple angles. The incidence of major cardiovascular events, defined as death, non-fatal myocardial infarction, stroke, and any revascularization, within 1-year of PCI was identified.
RESULTS: The prevalence of residual vasospasm in PR and PE was 15.1% (13 of 86) and 21.4% (12 of 56), respectively. Wavy pattern was the major shape of the residual vasospasm. Polygonal-patterned lumen was more frequently observed in PR than in PE (38.5 vs. 8.3 %). The polygonal-patterned lumens had significantly larger lipid arcs (257.9 vs. 78.0 °; P<0.01), and significantly smaller areas (1.27 vs. 1.88 mm2; P=0.05) than wavy-patterned lumens. Residual vasospasm had a prognostic impact on PR but not PE at 1-year of successful primary PCI.
CONCLUSION: Considerable proportion of ACS including both PR and PE had residual vasospasm with variable morphological feature and different prognostic impact.
Patients will be randomized into 3 groups. The patients will lay in the supine position, in the control group and 20 and 30 degrees head up position in other two groups. Each patient will be preoxygenated with well fitting anaesthesia face mask with FiO2 of 100% at least 6L of flow until the ETO2 reaches concentration of 85%. The angle (20 or 30 degrees) formed by the patients' bodies (hips and feet parallel to the ground, lifting the back from the ground plane) with the ground will be measured with a spirit level, angle meter, and confirmed with a smartphone application. The time to reach ETO2 85% by starting preoxygenation in patients will be measured and recorded with a stopwatch. When the target is reached, anesthesia induction will be performed and the patients will be intubated. After the start of the intubation attempt, the stopwatch will be started again, after intubation, the patient will be ventilated with a balloon once and the location of the tube will be confirmed, the circuit will be separated and SpO2 will be expected to go down to the level of 92 % and recorded during this time.
In premarketing clinical studies, there were seven reports of nefazodone overdose alone or in combination with other pharmacological agents. The amount of nefazodone ingested ranged from 1000 mg to 11,200 mg. Commonly reported symptoms from overdose of nefazodone included nausea, vomiting, and somnolence. One nonstudy participant took 2000 to 3000 mg of nefazodone with methocarbamol and alcohol; this person reportedly experienced a convulsion (type not documented). None of these patients died.

In postmarketing experience, overdose with nefazodone alone and in combination with alcohol and/or other substances has been reported. Commonly reported symptoms were similar to those reported from overdose in premarketing experience. While there have been rare reports of fatalities in patients taking overdoses of nefazodone, predominantly in combination with alcohol and/or other substances, no causal relationship to nefazodone has been established.
Gliomas are diffusely infiltrating brain tumors whose prognosis is strongly influenced by their extent of invasion into the surrounding brain tissue. While lower-grade gliomas present more circumscribed borders, high-grade gliomas are aggressive tumors with widespread brain infiltration and dissemination. Glioblastoma (GBM) is known for its high invasiveness and association with poor prognosis. Its low survival rate is due to the certainty of its recurrence, caused by microscopic brain infiltration which makes surgical eradication unattainable. New insights into GBM biology at the single-cell level have enabled the identification of mechanisms exploited by glioma cells for brain invasion. In this review, we explore the current understanding of several molecular pathways and mechanisms used by tumor cells to invade normal brain tissue. We address the intrinsic biological drivers of tumor cell invasion, by tackling how tumor cells interact with each other and with the tumor microenvironment (TME). We focus on the recently discovered neuronal niche in the TME, including local as well as distant neurons, contributing to glioma growth and invasion. We then address the mechanisms of invasion promoted by astrocytes and immune cells. Finally, we review the current literature on the therapeutic targeting of the molecular mechanisms of invasion.
Idiopathic pulmonary fibrosis (IPF) is a scarring lung disease. It damages the air sacs that allow oxygen to be transferred into the blood and transported to vital organs. These changes make people with IPF cough and feel short of breath. It not known what causes the damage. People who get IPF are usually older than 40; it's a very serious illness that cannot be cured and gets worse over time. Statistics show that IPF is becoming more common in the UK but it's not known why. It can be difficult for doctors to tell if someone has IPF or another disease called asbestosis.
PURPOSE:To provide a transcutaneous absorbefacient composed of a specific benzylsulfoxide derivative and effective in promoting the permeation and absorption of a drug through the skin. CONSTITUTION:The objective transcutaneous absorbefacient is composed of a compound of formula I (R is >=6C hydrocarbon group; X is H, alkyl, alkenyl, halogen, NO2, acyl, NH2, acylamino, OH, carboxyl, alkoxycarbonyl or alkoxy). The compound is used in the form of tincture, ointment, cream, tape, etc., together with the drug to be administered. The amount of the compound in the preparation is 0.1-50wt.%, preferably 1-20wt.%. The compound of formula I can be easily produced by reacting a benzene derivative of formula II (Y is halogen, tosyloxy, etc.) with a thiol compound of formula RSH in the presence of a base and oxidizing the resultant benzylsulfide derivative of formula III with an oxidizing agent.
The present invention relates to a composition for improving cognitive functions, comprising somatostatin or cortistatin as an effective component and, more specifically, to a composition for improving cognitive functions, which activates somatostatin receptors to improve visual perception skills. Also, the present invention relates to a composition for preventing or treating cognitive disorders, comprising somatostatin or cortistatin as an effective component. According to the present invention, somatostatin or cortistatin may be used to directly activate the somatostatin receptors to reduce excitatory synaptic transmission to inhibitory neurons expressing parvalbumin genes and to improve selective reactivity to visual information within a cortical circuit. Also, the somatostatin of the present invention and its biological peptide analogue can maintain their structures stably, and unlike artificially produced peptides, show non toxicity, and thus can be safely implanted in a living body. Also, the present invention may find a direct application in the restoration of cognitive functions through inducing the activation of somatostatin receptors by implanting somatostatin or its neuropeptide analogue directly into the brain or cerebrospinal fluid of a patient with damaged brain cognitive functions. Furthermore, the present invention may be beneficially used in the development and in vivo applications of biological peptide analogue compounds and artificial peptide compounds for the purpose of improving signal transduction through the activation of somatostatin receptors in cortical neurons.
Ferroptosis is a form of programmed cell death involved in various types of acute kidney injury (AKI). It is characterized by inactivation of the selenoprotein, glutathione peroxidase 4 (GPX4), and upregulation of acyl-CoA synthetase long-chain family member 4 (ACSL4). Since urinary selenium binding protein 1 (SBP1/SELENBP1) is a potential biomarker for AKI, this study investigated whether SBP1 plays a role in AKI. First, we showed that SBP1 is expressed in proximal tubular cells in normal human kidney, but is significant downregulated in cases of AKI in association with reduced GPX4 expression and increased ACSL4 expression. In mouse renal ischemia-reperfusion injury (I/R), the rapid downregulation of SBP1 protein levels preceded downregulation of GPX4 and the onset of necrosis. In vitro, hypoxia/reoxygenation (H/R) stimulation in human proximal tubular epithelial (HK-2) cells induced ferroptotic cell death in associated with an acute reduction in SBP1 and GPX4 expression, and increased oxidative stress. Knockdown of SBP1 reduced GPX4 expression and increased the susceptibility of HK-2 cells to H/R-induced cell death, whereas overexpression of SBP1 reduced oxidative stress, maintained GPX4 expression, reduced mitochondrial damage, and reduced H/R-induced cell death. Finally, selenium deficiency reduced GPX4 expression and promoted H/R-induced cell death, whereas addition of selenium was protective against H/R-induced oxidative stress. In conclusion, SBP1 plays a functional role in hypoxia-induced tubular cell death. Enhancing SBP1 expression is a potential therapeutic approach for the treatment of AKI.
Six participants were bonded with 0.022 × 0.028 inch slot brackets (Ortho Smile) using pre-adjusted edgewise appliance with 0.022 MBT prescriptions. ocal periodontal injection of serum at weekly interval (3 times). The gingival fluid volume will measured once. Pain during treatment will be assessed using the FLACC scale and face scale.
OBJECTIVE: Monitoring trends in key population health indicators is important for informing health policies. The aim of this study was to examine population health trends in Canada over the past 30 years in relation to other countries.
METHODS: We used data on disability-adjusted life years (DALYs), years of life lost (YLL), years lived with disability, life expectancy (LE), and child mortality for Canada and other countries between 1990 and 2019 provided by the Global Burden of Disease Study.
RESULTS: Life expectancy, age-standardized YLL, and age-standardized DALYs all improved in Canada between 1990 and 2019, although the rate of improvement has leveled off since 2011. The top five causes of all-age DALYs in Canada in 2019 were neoplasms, cardiovascular diseases, musculoskeletal disorders, neurological disorders, and mental disorders. The greatest increases in all-age DALYs since 1990 were observed for substance use, diabetes and chronic kidney disease, and sense organ disorders. Age-standardized DALYs declined for most conditions, except for substance use, diabetes and chronic kidney disease, and musculoskeletal disorders, which increased by 94.6%, 14.6%, and 7.3% respectively since 1990. Canada's world ranking for age-standardized DALYs declined from 9th place in 1990 to 24th in 2019.
CONCLUSION: Canadians are healthier today than in 1990, but progress has slowed in Canada in recent years in comparison with other high-income countries. The growing burden of substance abuse, diabetes/chronic kidney disease, and musculoskeletal diseases will require continued action to improve population health.
The present invention includes peptide compositions for improving cellular communication mechanisms, repairing metabolic errors, and for treatment of AD, dementia and other neurological conditions. The proline rich peptide complexes (PRPC) of the present invention are isolated from colostrinin and can be added in nutritional and other food supplements. Additionally, the present invention describes novel communication system governing circa two hundreds of different types of cells in each mammal that modulates the activities of the organism through the biological computer present in every living cell. Different type of cells can communicate with other through biological computer connected with five different communication networks. In addition to the biological computer controls cell metabolism and function assigned to a given type of cell. Such system permits smooth cooperation between 10 17  cells forming the body. Within a communication system each network utilizes different types of signals, with about 69 different signals operating within each network. These numbers permit the formation of a circa of 10 99  combinations approaching the infinity and utilizing different types of signals. Practically each cell biological computer can recognize signals delivered by every one in the network.